Cox regression univariate analysis and model fit
| . | HR . | 95% CI . | P . | AIC . | C statistic (95% CI) . |
|---|---|---|---|---|---|
| PFS | |||||
| Cycle 1 | |||||
| UPEP positive | 1.3 | 0.6-3.2 | .519 | 151.9 | 0.5 (0.4-0.6) |
| iFLC elevated | 5.0 | 1.2-21.3 | .032 | 145.4 | 0.6 (0.5-0.7) |
| uIFE positive | 1.1 | 0.6-2.4 | .731 | 245.1 | 0.5 (0.5-0.6) |
| sFLC ratio abnormal | 7.5 | 1.0-54.7 | .048 | 237.5 | 0.6 (0.5-0.6) |
| Cycle 3 | |||||
| UPEP positive | 1.6 | 0.8-3.3 | .178 | 351.9 | 0.5 (0.5-0.6) |
| iFLC elevated | 2.3 | 1.3-4.4 | .008 | 346.3 | 0.6 (0.5-0.7) |
| uIFE positive | 1.7 | 1.0-3.1 | .077 | 405.8 | 0.6 (0.5-0.6) |
| sFLC ratio abnormal | 6.8 | 2.5-19.0 | <.001 | 386.3 | 0.7 (0.6-0.7) |
| Postconsolidation | |||||
| iFLC elevated | 2.7 | 1.4-5.4 | .004 | — | — |
| sFLC ratio abnormal | 3.1 | 1.4-6.8 | .006 | — | — |
| OS | |||||
| Cycle 1 | |||||
| UPEP positive | 0.3 | 0.04-2.6 | .314 | 49.6 | 0.6 (0.5-0.7) |
| iFLC elevated* | — | — | — | 45.3 | 0.7 (0.6-0.7) |
| uIFE positive | 2.4 | 0.5-11.3 | .270 | 76.6 | 0.6 (0.5-0.7) |
| sFLC ratio abnormal* | — | — | — | 72.5 | 0.6 (0.5-0.6) |
| Cycle 3 | |||||
| UPEP positive | 0.9 | 0.2-4.0 | .891 | 116.0 | 0.5 (0.4-0.6) |
| iFLC elevated | 2.2 | 0.7-6.6 | .164 | 114.0 | 0.6 (0.5-0.7) |
| uIFE positive | 1.4 | 0.5-3.8 | .537 | 145.8 | 0.6 (0.5-0.7) |
| sFLC ratio abnormal | 7.8 | 1.0-58.5 | .047 | 139.0 | 0.7 (0.6-0.7) |
| . | HR . | 95% CI . | P . | AIC . | C statistic (95% CI) . |
|---|---|---|---|---|---|
| PFS | |||||
| Cycle 1 | |||||
| UPEP positive | 1.3 | 0.6-3.2 | .519 | 151.9 | 0.5 (0.4-0.6) |
| iFLC elevated | 5.0 | 1.2-21.3 | .032 | 145.4 | 0.6 (0.5-0.7) |
| uIFE positive | 1.1 | 0.6-2.4 | .731 | 245.1 | 0.5 (0.5-0.6) |
| sFLC ratio abnormal | 7.5 | 1.0-54.7 | .048 | 237.5 | 0.6 (0.5-0.6) |
| Cycle 3 | |||||
| UPEP positive | 1.6 | 0.8-3.3 | .178 | 351.9 | 0.5 (0.5-0.6) |
| iFLC elevated | 2.3 | 1.3-4.4 | .008 | 346.3 | 0.6 (0.5-0.7) |
| uIFE positive | 1.7 | 1.0-3.1 | .077 | 405.8 | 0.6 (0.5-0.6) |
| sFLC ratio abnormal | 6.8 | 2.5-19.0 | <.001 | 386.3 | 0.7 (0.6-0.7) |
| Postconsolidation | |||||
| iFLC elevated | 2.7 | 1.4-5.4 | .004 | — | — |
| sFLC ratio abnormal | 3.1 | 1.4-6.8 | .006 | — | — |
| OS | |||||
| Cycle 1 | |||||
| UPEP positive | 0.3 | 0.04-2.6 | .314 | 49.6 | 0.6 (0.5-0.7) |
| iFLC elevated* | — | — | — | 45.3 | 0.7 (0.6-0.7) |
| uIFE positive | 2.4 | 0.5-11.3 | .270 | 76.6 | 0.6 (0.5-0.7) |
| sFLC ratio abnormal* | — | — | — | 72.5 | 0.6 (0.5-0.6) |
| Cycle 3 | |||||
| UPEP positive | 0.9 | 0.2-4.0 | .891 | 116.0 | 0.5 (0.4-0.6) |
| iFLC elevated | 2.2 | 0.7-6.6 | .164 | 114.0 | 0.6 (0.5-0.7) |
| uIFE positive | 1.4 | 0.5-3.8 | .537 | 145.8 | 0.6 (0.5-0.7) |
| sFLC ratio abnormal | 7.8 | 1.0-58.5 | .047 | 139.0 | 0.7 (0.6-0.7) |
Bold values in the table body represent statistically significant results.
—, results not reported; AIC, Akaike information criterion; HR, hazard ratio.
None and 1 event were reported for patients with normal iFLC and FLC ratio, respectively, resulting in broad CIs.